Research programme: checkpoint kinase 1 inhibitors - Cascadian/SentinelAlternative Names: CASC-578; S024; S070; S081; S091; S158; S209
Latest Information Update: 09 Jun 2016
At a glance
- Originator Sentinel Oncology
- Developer Cascadian Therapeutics; Sentinel Oncology
- Class Small molecules
- Mechanism of Action Checkpoint kinase 1 inhibitors; DNA repair inhibitors; Phosphotransferase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer